Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 11, 2014, Pages 1190-1197

  Butzkueven, Helmut ^a,b   Kappos, Ludwig ^c   Pellegrini, Fabio ^d   Trojano, Maria ^e   Wiendl, Heinz ^f   Patel, Radhika N ^g   Zhang, Annie ^g   Hotermans, Christophe ^g   Belachew, Shibeshih ^g  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Laboratorio Angela Valenti dei Fattori Genetici e Ambientali di Rischio Trombotico   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; ALPHA4 INTEGRIN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABORTION; ADULT; ALLERGIC REACTION; ANEMIA; ARTICLE; BACKACHE; BLADDER DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; CONVERSION DISORDER; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPTIC STATE; EXPANDED DISABILITY STATUS SCALE; EXTRAVASATION; FEMALE; FEMUR FRACTURE; FOLLOW UP; HEADACHE; HEART INFARCTION; HEMORRHOID; HUMAN; HYPERTENSION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION; INTERVERTEBRAL DISK HERNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENORRHAGIA; METRORRHAGIA; MIGRAINE; MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PANIC; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; PSYCHOSOMATIC DISORDER; RELAPSE; SCORING SYSTEM; SEIZURE; SUICIDE; SUICIDE ATTEMPT; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UTERUS MYOMA; VERTIGO; DRUG EFFECTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTEGRIN ALPHA4; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901725946     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-306936     Document Type: Article

References (17)

1. Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004;4:571-80.
2. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
3. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256:405-15.
4. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.
5. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
6. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011;17:970-9.
7. Kappos L, Wu S, eds. Interactive Training DVD-ROM for a standardised, quantified neurological examination and assessment of Kurtzke's Functional Systems and Expanded Disability Status Scale in Multiple Sclerosis. Basel, Switzerland: University Hospital Basel Department of Neurology, 2007.
8. O'Connor PW, Goodman AD, Kappos L, et al. Updated efficacy and safety of natalizumab in patients who participated in the STRATA study [abstract]. Mult Scler 2010;16(Suppl 10):S162.
9. Bozic C, Cristiano LM, Hyde R, et al. Utilisation and safety of natalizumab in patients with relapsing multiple sclerosis [abstract]. Mult Scler 2010;16(Suppl 10):S315.
10. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745-58.
11. TYSABRI® (natalizumab) injection. Full prescribing information. http://www.tysabri.com/pdfs/I61061-13-PI.pdf (accessed 5 Aug 2013).
12. Biogen Idec MedInfo. https://medinfo.biogenidec.com (accessed 9 Dec 2013).
13. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80.
14. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
15. Putzki N, Yaldizli O, Bühler R, et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 2010;63:101-6.
16. Sangalli F, Moiola L, Bucello S, et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 2011;31(Suppl 3):299-302.
17. Kallweit U, Jelcic I, Braun N, et al. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol 2012;35:77-80.